Ahz move, page-21

Hi Musky45... and all

Thankyou for providing the data upon which to base your conclusions ... way to go!

I will show my ignorance by asking if your could please explain, because I really don't understand, the interplay between revenue, receipts and receivables ... as in my extract from your info below (fingers crossed it comes through OK) ... see that in Q4 2014 the receipts and receivables total the revenue ... seems simple enough .. but then it seems to be quite different in recent and future times ... shouldn't they be the same?

	Column 1	Column 2	Column 3	Column 4	Column 5
0	​	Q4-2014​	Q3-2017​	Q4 est-2017​	Q2 est-2018​
1	Revenue​	$2,500​	$5,000​	$5,750​	$7,935​
2	​	​	​	​	​
3	​	​	​	​	​
4	Receipts​	$2,316​	$5,164​	$5,400​	$7,281​
5	Receivables​	$184​	$4,000​	$4,350​	$5,223​
6	​	$2,500​	$9,164​	$9,750​	$12,504​

​

In any case ... let's just say that when the share price reflects that investors can see a profitable future ahead ... say late 2018 as example ... and we have a high growth multiplier of (say) 30 ...  what do you think the price per share would be assuming nothing different in imunotherapies division ... say the much hyped 2020 mid-year Q2?

Part of my frustration is that in years past I assumed that the cardiac surgeons would "grab" our cardiocell because it would mean no repeat heart operation at age 8 for the hole-in-the-heart kids ... but I was wrong .. compared with (say) if we suddenly had a cure for HSV2 .. no sales effort needed .. just internet sales out the door as fast as ...
Anyway Musky, thank you for your fulsome reply to my earlier question ...
cheers all
D
.

​